DNSP-11 Research

DNSP-11 research is entirely preclinical, and every finding below comes from a test tube, a cell line, a rat or a macaque ^{[1][2][3][4][5][6][7]}. No published study has given DNSP-11 to a human, across the eight records PubMed returns for the term ^[13]. DNSP-11 is a research compound and it is not for human consumption. Every dopaminergic result on DNSP-11 comes from one patent-holding laboratory ^{[1][3][4][5][14]}.

What DNSP-11 is

DNSP-11, or dopamine neuron stimulating peptide-11, is an 11-residue amidated peptide with the sequence PPEAPAEDRSL-amide ^[1]. That sequence sits in the proregion of the human pre-proGDNF precursor, which is cut away and discarded when mature GDNF is made ^[1]. DNSP-11 is a fragment of GDNF's packaging, not of GDNF itself ^[1].

Its presence in the body is predicted, not demonstrated. The founding paper describes the GDNF prosequence as predicting dibasic endopeptidase sites that would yield an amidated 11-mer ^[1]. It later calls DNSP-11 a peptide possibly derived from that prosequence ^[1]. A rat immunohistochemistry study found antibody signal in the substantia nigra, ventral tegmental area, dentate gyrus and locus coeruleus ^[6]. Those authors state that the antibody does not distinguish the 11-mer from the proGDNF form ^[1][6]. They also note that sequence homologues such as NPY and Tfg exist ^[6]. Free DNSP-11 has not been shown to occur in an animal, let alone a person.

No CAS number is declared for DNSP-11, and PubChem holds no compound or substance record for the name or the sequence ^[15]. The declared formula C50H81N15O18 and mass near 1,180.3 g/mol both compute from the published sequence, so the two identifiers verify each other ^[1][15].

Molecules easy to confuse with DNSP-11

DNSP-5 and DNSP-17 come from the same program, and their results are their own rather than DNSP-11's ^[2][8]. BEP is the rat homolog reported by a Finnish group ^[9]. GFRα1-targeting 12-mer phage-display peptides do bind GFRα1, which is mechanistically the opposite of DNSP-11 ^[10].

DNSP-11 mechanism of action

No receptor for DNSP-11 is identified in any paper retrieved for this article ^[1][3]. The founding study tested binding to GFRα1, GDNF's own co-receptor, by pull-down and by direct ELISA ^[1]. Both in vitro assays were negative for DNSP-11 while GDNF bound as expected, and that paper's proteomics returned no protein from the GDNF, GFRα1 or RET pathway ^[1]. Those authors conclude that it likely signals through pathways not directly involving GFRα1 ^[1].

That negative blocks any transfer of GDNF's biology to this peptide, because GDNF signals through a co-receptor that DNSP-11 does not bind ^[1]. GDNF's clinical record is a separate literature about a different, much larger molecule. It is not evidence about DNSP-11 in either direction.

In vitro, DNSP-11 prevented cytochrome c release from mitochondria in nutrient-deprived B65 cells, and a single treatment of MN9D dopaminergic cells increased ERK1/2 phosphorylation ^[1][3]. In HEK-293 cells, a human embryonic kidney line rather than a neuron, it gave concentration-dependent protection against staurosporine and 3-nitropropionate ^[2].

Preclinical findings, positive and null

In vitro, DNSP-11 supported survival of fetal mesencephalic neurons and increased neuritic outgrowth, and in MN9D cells it reduced 6-OHDA-induced TUNEL positivity and caspase-3 activity ^[1]. In rats, a single injection into the normal substantia nigra raised resting dopamine and its metabolites for up to 28 days ^[1]. In a 6-OHDA rat model it improved apomorphine-induced rotational behavior and raised nigral dopamine tissue levels ^[1].

The same paper also reports that no significant change in dopamine, DOPAC or HVA was observed in the lesioned rat striatum, and that those data were not shown ^[1]. The striatum is where dopaminergic terminals degenerate in Parkinson's disease.

A later rat study from the same laboratory asked whether DNSP-11 changes dopamine neuron function, and largely found that it does not ^[3]. Four weeks after treatment, microdialysis showed no significant change in dopamine release, and spontaneous locomotor activity was unchanged ^[3]. Potassium-evoked release rose in specific subregions of the striatum at two weeks, but not at one or four weeks ^[3].

Repeated intranasal delivery in normal rats raised dopamine turnover in striatum and substantia nigra, but only at the highest level tested ^[4]. In 6-OHDA-lesioned rats it reduced d-amphetamine-induced rotation at two weeks and increased sparing of tyrosine-hydroxylase-positive neurons ^[4]. That sparing was confined to a specific sub-region of the lesioned substantia nigra pars compacta ^[4]. In those same lesioned rats dopamine turnover decreased in the lesioned striatum, the opposite direction to the rise seen in normal animals ^[4].

The Rhesus macaque is the highest species in which DNSP-11 has been tested ^[5]. Repeated intranasal delivery over ten weeks produced bilateral striatal target engagement, judged by dopamine metabolite changes ^[5]. No adverse behavioral effects and no weight loss were observed in those animals ^[5]. Its authors call the work a proof-of-concept study reporting initial data ^[5]. No motor, behavioral or neuroprotection efficacy endpoint is reported for the MPTP-treated animals ^[5].

Human research on DNSP-11

There is no human research on DNSP-11: a PubMed search for the term returns eight records, and every DNSP-11 finding in them is in vitro, rat or macaque ^[13]. ClinicalTrials.gov returns zero studies for both DNSP-11 and DNSP11, and the EU register and ISRCTN return nothing ^[13]. openFDA returns no label, no adverse event report and no substance registry record ^[13].

DNSP-11 has never been submitted for regulatory review anywhere, and it was not withdrawn, refused or rejected, because no application appears on any public record ^[13]. There is no human safety information in either direction, and the absence of observed adverse effects applies to rats and macaques only ^[4][5].

Independence, replication and conflicts of interest

Every dopaminergic and Parkinson's finding on DNSP-11 comes from one research program centered on the University of Kentucky ^{[1][3][4][5][6]}. No independent group has attempted to replicate any of them. This is a replication gap rather than a failed replication, because nobody outside that program has tried.

Exactly one unaffiliated laboratory has worked with the peptide at all ^[7]. A group at the NIA-NIH commissioned its synthesis and ran a thioflavin T amyloid inhibition assay ^[7]. In that test tube experiment, DNSP-11 inhibited fibrillation of IAPP37 by 24.1% (p = 0.003) and of amyloid-beta 42 by 61.9% (p < 0.0001) ^[7]. The assay carried a negative control, and DNSP-11 alone did not bind the thioflavin T reporter ^[7]. No cellular, animal or human follow-up to that in vitro result has been published ^[7]. It says nothing about the Parkinson's claims, and it is not evidence of a benefit in any disease.

The originating group's patent interest is disclosed, and it is live. The founding paper states that four of its authors declare three patents pending on the reported findings, and the 2014 rat paper declares four ^[1][3]. US Patent 9,402,875 B2 was granted in August 2016 to the University of Kentucky Research Foundation, naming Bradley, Gash and Gerhardt and claiming PPEAPAEDRSL-amide ^[14]. It is recorded as active, with an adjusted expiry in February 2028 ^[14]. No retraction, erratum or expression of concern exists in this literature ^[13]. The patent holders produced all of the dopaminergic evidence.

Current research directions and limitations

The Kentucky program has published no new DNSP-11 data since 2019 ^[13]. No new dopaminergic or Parkinson's finding on the peptide has appeared from anyone since then ^[13]. Work on drugging the GDNF pathway has continued without it ^[12]. A 2026 paper reports 12-mer peptides that bind GFRα1 and mimic GDNF bioactivity in vitro ^[10]. A 2025 review of GDNF isoforms presents small isoforms, not DNSP-11, as the avenue of interest ^[11].

Two limits apply to the evidence summarized here. The full texts of the 2014, 2015 and 2018 animal papers were not retrieved, so their results sections may hold further unreported nulls ^[3][4][5]. No dedicated search for a DNSP-11 receptor was run, so the absence of one rests on the papers retrieved rather than on an exhaustive review ^[1].

Conclusion

DNSP-11 is an early-stage research peptide with a small evidence base whose dopaminergic findings all come from one laboratory ^{[1][3][4][5][6]}. Its founding paper is strongly positive, and a later paper from the same laboratory is largely negative on dopamine neuron function in rats ^[1][3]. It does not bind GDNF's co-receptor, and no receptor of its own has been identified in the papers retrieved ^[1]. No human study of DNSP-11 has been published ^[13].

Frequently Asked Questions

Has DNSP-11 been tested in humans? No published study has given DNSP-11 to a human, across the eight records PubMed returns for the term ^[13]. ClinicalTrials.gov returns zero registered studies for both DNSP-11 and DNSP11 ^[13]. Every published DNSP-11 finding is in vitro, rat or macaque ^{[1][2][3][4][5][6][7]}.

Is DNSP-11 a fragment of GDNF? It comes from the proregion of the pre-proGDNF precursor, which is cut away and discarded when mature GDNF is made, so it is not part of the mature protein ^[1]. The founding paper found no binding between DNSP-11 and GDNF's co-receptor GFRα1 ^[1]. GDNF's own clinical literature is therefore not evidence about DNSP-11.

Has any independent group replicated the DNSP-11 findings? No independent group has attempted to replicate the dopaminergic findings, which all come from one research program ^{[1][3][4][5][6]}. Exactly one unaffiliated laboratory has worked with the peptide, in an unrelated in vitro amyloid aggregation assay with no published follow-up ^[7].

References

1. 1

   Bradley LH, Fuqua J, Richardson A, et al. Dopamine neuron stimulating actions of a GDNF propeptide. PLoS One. 2010 Mar 18;5(3):e9752. PMID 20305789. DOI: 10.1371/journal.pone.0009752 (full text at PMC2841203; competing-interests statement read from the live PubMed record)
2. 2

   Kelps KA, Turchan-Cholewo J, Hascup ER, et al. Evaluation of the physical and in vitro protective activity of three synthetic peptides derived from the pro- and mature GDNF sequence. Neuropeptides. 2011 Jun;45(3):213-8. PMID 21507484. DOI: 10.1016/j.npep.2011.03.003
3. 3

   Fuqua JL, Littrell OM, Lundblad M, et al. Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro. Peptides. 2014 Apr;54:1-8. PMID 24406899. DOI: 10.1016/j.peptides.2013.12.007 (conflict statement on the live record: "GAG, DMG, LHB declare that 4 patents are pending related to these studies")
4. 4

   Stenslik MJ, Potts LF, Sonne JW, et al. Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease. J Neurosci Methods. 2015 Aug 15;251:120-9. PMID 25999268. DOI: 10.1016/j.jneumeth.2015.05.006
5. 5

   Stenslik MJ, Evans A, Pomerleau F, et al. Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques. J Neurosci Methods. 2018 Jun 1;303:30-40. PMID 29614295. DOI: 10.1016/j.jneumeth.2018.03.006
6. 6

   Sonne JWH, Groshong JS, Seavey C, Gash DM. Spatial and temporal immunoreactivity in the rat brain using an affinity purified polyclonal antibody to DNSP-11. J Chem Neuroanat. 2019 Oct;100:101664. PMID 31394198. DOI: 10.1016/j.jchemneu.2019.101664
7. 7

   Liu QR, Zhu M, Chen Q, et al. Novel hominid-specific IAPP isoforms: potential biomarkers of early Alzheimer's disease and inhibitors of amyloid formation. Biomolecules. 2023 Jan 13;13(1):167. PMID 36671553. DOI: 10.3390/biom13010167 (Laboratory of Clinical Investigation, NIA-NIH, Baltimore; PublicationType "Research Support, N.I.H., Intramural"; no author overlap with the University of Kentucky program; spells the peptide "DNSP11" unhyphenated)
8. 8

   Littrell OM, Fuqua JL, Richardson AD, et al. A synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function. Neuropeptides. 2013 Feb;47(1):43-9. PMID 22981157. DOI: 10.1016/j.npep.2012.08.004 (this paper is about DNSP-5, a different molecule)
9. 9

   Immonen T, Alakuijala A, Hytönen M, et al. A proGDNF-related peptide BEP increases synaptic excitation in rat hippocampus. Exp Neurol. 2008 Apr;210(2):793-6. PMID 18280470. DOI: 10.1016/j.expneurol.2007.12.018 (rat homolog, not the peptide described here)
10. 10

    Atkinson EA, Liu T, Fowler M, et al. Peptides targeting GDNF family receptor alpha 1 (GFRα1) mimic glial cell line-derived neurotrophic factor (GDNF) bioactivity. J Med Chem. 2026 May 28;69(10):11914-11925. PMID 42100797. DOI: 10.1021/acs.jmedchem.5c03413 (a different peptide class; these bind GFRα1, DNSP-11 does not)
11. 11

    Parshina VV, Revishchin AV, Pavlova GV. [Isoforms of glial cell line-derived neurotrophic factor and their therapeutic potential]. Zh Vopr Neirokhir Im N N Burdenko. 2025;89(6. Vyp. 2):38-43. PMID 41527797. DOI: 10.17116/neiro20258906238 (Russian-language review; the only review among the eight PubMed records for "DNSP-11")
12. 12

    Sidorova YA, Saarma M. Small molecules and peptides targeting glial cell line-derived neurotrophic factor receptors for the treatment of neurodegeneration. Int J Mol Sci. 2020 Sep 8;21(18):6575. PMID 32911810. DOI: 10.3390/ijms21186575
13. 13

    Database and registry sweep, re-run live for this draft on 2026-08-28. PubMed E-utilities esearch for "DNSP-11" returns count 8, with PMIDs 20305789, 21507484, 24406899, 25999268, 29614295, 31394198, 36671553 and 41527797; all eight were resolved through esummary and efetch. ClinicalTrials.gov API v2 with countTotal=true returns totalCount 0 for "DNSP-11" and 0 for "DNSP11". The EU Clinical Trials Register and ISRCTN return no matching records. openFDA drug/label (openfda.substance_name), drug/ndc (generic_name), drug/event (patient.drug.openfda.substance_name) and other/substance (names.name) all return NOT_FOUND for "DNSP-11". Correction-linkage fields across the retrieved records show no retraction, erratum or expression of concern.
14. 14

    US Patent 9,402,875 B2, "Amidated dopamine neuron stimulating peptide restoration of mitochondrial activity." Granted 2 August 2016; assignee University of Kentucky Research Foundation; inventors Luke H. Bradley, Don Marshall Gash and Greg A. Gerhardt; legal status active; adjusted expiration 11 February 2028; claims PPEAPAEDRSL-amide as SEQ ID NO: 4. Published as application US20130065830A1 on 14 March 2013. Record retrieved 2026-08-28.
15. 15

    NCBI PubChem PUG-REST, retrieved 2026-08-28. Compound-name lookups for "DNSP-11" and for the bare sequence "PPEAPAEDRSL" both return HTTP 404 PUGREST.NotFound, as do the substance-level lookup and the full Pro-Pro-Glu-Ala-Pro-Ala-Glu-Asp-Arg-Ser-Leu residue name. No CID and no SID exists. The formula and mass statement in the body is an independent calculation from PPEAPAEDRSL-amide, not a PubChem retrieval: residue masses sum to 1163.25, plus water gives 1181.27, and C-terminal amidation gives 1180.28, with a residue-composition formula of C50H81N15O18.